ABU DHABI, 11 March — A total of 1,000 volunteers in UAE received two doses of a Russian human adenovirus-based COVID-19 vaccine as a part of trials in the country, Abu Dhabi Media Office announced.
This trial is a part of the scientific data collection phase, as the inoculation phase of the trials has been completed, according to Abu Dhabi Media Office. The trials’ findings will be combined with existing global research findings, and interim results will be released by April 2021.
The Russian adenovirus-based vaccine has reportedly shown a 91.6% efficacy rate against COVID-19.
Volunteers who received the vaccine doses will be monitored for 180 days, to monitor their immune response as a part of the Russian vaccine trials.
The prominent international medical journal The Lancet reported the recent interim results from Phase III clinical trials of the Russian human adenovirus-based vaccine, which showed high efficacy of 91.6%, as well as strong immunogenicity and safety results.
The first two earlier phases of the vaccine clinical trials, which were also published in The Lancet, reported stable humoral and cellular immune response among the volunteers.
Source: Gulf News/Agencies
